Group leader: Martin Ingelsson
Visiting address: Dag Hammarskjölds väg 20, Uppsala Science Park
The aim of our research is to understand, prevent, diagnos and cure diseases in the elderly population, like dementia, diabetes and cardiovascular diease.
In clinical trials we develop new drugs against these diseases. We are conducting epidemiological and genetic studies to understand the interplay between genes and environment in complex disorders. In clinical research we aim to develop better diagnostic instruments for Alzheimer’s disease. Our molecular research is aiming at disease mechanisms of Alzheimer’s disease and related disorders. The starting point for these studies is genetic discoveries to understand molecular mechanisms involved in dementias. Model systems have been developed in transgenic animals and in cell cultures to test new treatment principles.
alpha-Synuclein strains target distinct brain regions and cell types
Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure
Longitudinal changes in the frequency of mosaic chromosome Y loss in peripheral blood cells of aging men varies profoundly between individuals
Independent Ageing in Very Old Swedish Men.
Leire Almandoz Gil (2018)
Characterization of Physiological and Pathological Alpha-Synuclein: Implications for Parkinson’s Disease and Related Disorders.
Elisabeth Nikitidou (2018)
Cellular responses to amyloid-beta protofibrils: Focus on astrocytes, extracellular vesicles and antibody treatment.
Xiaotian T. Fang (2018)
Preclinical PET imaging of Alzheimer's disease progression.